Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The VEGF family (VEGF-A, VEGF-B, VEGF-C, PlGF) comprises secreted proteins that control vascular and lymphatic formation and remodeling. These growth factors bind and activate VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), triggering intracellular signaling cascades essential for angiogenesis, lymphangiogenesis, and vascular permeability. Dysregulation is implicated in cancer, inflammatory processes, and vascular diseases. Multiple approved drugs neutralize these proteins or block their receptors, and their inhibition poses notable but manageable safety risks.
Ligand neutralization (monoclonal antibody binds VEGF-A/PlGF, blocks receptor interaction), decoy receptor binding (fused VEGFR extracellular domains that sequester VEGF), inhibition of receptor tyrosine kinase activity (small molecules block VEGFR signaling), RNA aptamer binding (direct inhibition of VEGF-A).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VEGF Family (VEGF-A, VEGF-B, VEGF-C, PlGF) (VEGF/PlGF Family).